These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22115131)

  • 21. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
    Piccart MJ; Lamb H; Vermorken JB
    Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.
    Buyana B; Naki T; Alven S; Aderibigbe BA
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion.
    Smith E; Brock AP
    Br J Cancer; 1988 Jun; 57(6):548-52. PubMed ID: 3044430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
    Tang CH; Parham C; Shocron E; McMahon G; Patel N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
    Bruno PM; Liu Y; Park GY; Murai J; Koch CE; Eisen TJ; Pritchard JR; Pommier Y; Lippard SJ; Hemann MT
    Nat Med; 2017 Apr; 23(4):461-471. PubMed ID: 28263311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds.
    Paschke R; Kalbitz J; Paetz C; Luckner M; Mueller T; Schmoll HJ; Mueller H; Sorkau E; Sinn E
    J Inorg Biochem; 2003 Apr; 94(4):335-42. PubMed ID: 12667704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A better platinum-based anticancer drug yet to come?
    Olszewski U; Hamilton G
    Anticancer Agents Med Chem; 2010 May; 10(4):293-301. PubMed ID: 20187870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lobaplatin: a new antitumour platinum drug.
    McKeage MJ
    Expert Opin Investig Drugs; 2001 Jan; 10(1):119-28. PubMed ID: 11116285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oxaliplatin: the first DACH platinum in clinical practice].
    Soulié P; Raymond E; Brienza S; Cvitkovic E
    Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
    Mohammed MQ; Retsas S
    Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacokinetic properties of platinium derivatives].
    Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
    Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
    Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
    Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinums: extending their therapeutic spectrum.
    Muggia FM; Fojo T
    J Chemother; 2004 Nov; 16 Suppl 4():77-82. PubMed ID: 15688617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Developments in the Field of Anticancer Platinum Complexes.
    Galanski MS
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):285-95. PubMed ID: 18221042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.